Alemtuzumab, a CD52 monoclonal antibody, is increasingly used for treating advanced cutaneous T-cell lymphomas including Sézary syndrome (SS). While injection site reactions are common, the finding of localized cutaneous hemophagocytosis at the injection site without systemic hemophagocytosis is rare.
Article InformationCorresponding Author: Christiane Querfeld, MD, PhD, Dermatology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 160 E 53rd St, New York, NY 10022 (email@example.com).
Published Online: July 16, 2014. doi:10.1001/jamadermatol.2013.10615.
Conflict of Interest Disclosures: None reported.